Cargando…

Merlin deficiency alters the redox management program in breast cancer

The expression of Merlin tumor suppressor protein encoded by Neurofibromin 2 (NF2) gene is remarkably decreased in metastatic breast cancer tissues. In order to recapitulate clinical evidence, we generated a unique, conditional Nf2‐knockout (Nf2(−/−)) mouse mammary tumor model. Merlin‐deficient brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mota, Mateus, Metge, Brandon J., Hinshaw, Dominique C., Alsheikh, Heba A., Chen, Dongquan, Samant, Rajeev S., Shevde, Lalita A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024723/
https://www.ncbi.nlm.nih.gov/pubmed/33410252
http://dx.doi.org/10.1002/1878-0261.12896
_version_ 1783675369378807808
author Mota, Mateus
Metge, Brandon J.
Hinshaw, Dominique C.
Alsheikh, Heba A.
Chen, Dongquan
Samant, Rajeev S.
Shevde, Lalita A.
author_facet Mota, Mateus
Metge, Brandon J.
Hinshaw, Dominique C.
Alsheikh, Heba A.
Chen, Dongquan
Samant, Rajeev S.
Shevde, Lalita A.
author_sort Mota, Mateus
collection PubMed
description The expression of Merlin tumor suppressor protein encoded by Neurofibromin 2 (NF2) gene is remarkably decreased in metastatic breast cancer tissues. In order to recapitulate clinical evidence, we generated a unique, conditional Nf2‐knockout (Nf2(−/−)) mouse mammary tumor model. Merlin‐deficient breast tumor cells and Nf2(−/−) mouse embryonic fibroblasts (MEFs) displayed a robustly invasive phenotype. Moreover, Nf2(−/−) MEFs presented with notable alterations in redox management networks, implicating a role for Merlin in redox homeostasis. This programmatic alteration resonated with pathways that emerged from breast tumor cells engineered for Merlin deficiency. Further investigations revealed that NF2‐silenced cells supported reduced activity of the Nuclear factor, erythroid 2 like 2 antioxidant transcription factor, concomitant with elevated expression of NADPH oxidase enzymes. Importantly, mammary‐specific Nf2(−/−) in an Mouse mammary tumor virus Neu + murine breast cancer model demonstrated accelerated mammary carcinogenesis in vivo. Tumor‐derived primary organoids and cell lines were characteristically invasive with evidence of a dysregulated cellular redox management system. As such, Merlin deficiency programmatically influences redox imbalance that orchestrates malignant attributes of mammary/breast cancer.
format Online
Article
Text
id pubmed-8024723
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80247232021-04-12 Merlin deficiency alters the redox management program in breast cancer Mota, Mateus Metge, Brandon J. Hinshaw, Dominique C. Alsheikh, Heba A. Chen, Dongquan Samant, Rajeev S. Shevde, Lalita A. Mol Oncol Research Articles The expression of Merlin tumor suppressor protein encoded by Neurofibromin 2 (NF2) gene is remarkably decreased in metastatic breast cancer tissues. In order to recapitulate clinical evidence, we generated a unique, conditional Nf2‐knockout (Nf2(−/−)) mouse mammary tumor model. Merlin‐deficient breast tumor cells and Nf2(−/−) mouse embryonic fibroblasts (MEFs) displayed a robustly invasive phenotype. Moreover, Nf2(−/−) MEFs presented with notable alterations in redox management networks, implicating a role for Merlin in redox homeostasis. This programmatic alteration resonated with pathways that emerged from breast tumor cells engineered for Merlin deficiency. Further investigations revealed that NF2‐silenced cells supported reduced activity of the Nuclear factor, erythroid 2 like 2 antioxidant transcription factor, concomitant with elevated expression of NADPH oxidase enzymes. Importantly, mammary‐specific Nf2(−/−) in an Mouse mammary tumor virus Neu + murine breast cancer model demonstrated accelerated mammary carcinogenesis in vivo. Tumor‐derived primary organoids and cell lines were characteristically invasive with evidence of a dysregulated cellular redox management system. As such, Merlin deficiency programmatically influences redox imbalance that orchestrates malignant attributes of mammary/breast cancer. John Wiley and Sons Inc. 2021-02-01 2021-04 /pmc/articles/PMC8024723/ /pubmed/33410252 http://dx.doi.org/10.1002/1878-0261.12896 Text en © 2021 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Mota, Mateus
Metge, Brandon J.
Hinshaw, Dominique C.
Alsheikh, Heba A.
Chen, Dongquan
Samant, Rajeev S.
Shevde, Lalita A.
Merlin deficiency alters the redox management program in breast cancer
title Merlin deficiency alters the redox management program in breast cancer
title_full Merlin deficiency alters the redox management program in breast cancer
title_fullStr Merlin deficiency alters the redox management program in breast cancer
title_full_unstemmed Merlin deficiency alters the redox management program in breast cancer
title_short Merlin deficiency alters the redox management program in breast cancer
title_sort merlin deficiency alters the redox management program in breast cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024723/
https://www.ncbi.nlm.nih.gov/pubmed/33410252
http://dx.doi.org/10.1002/1878-0261.12896
work_keys_str_mv AT motamateus merlindeficiencyalterstheredoxmanagementprograminbreastcancer
AT metgebrandonj merlindeficiencyalterstheredoxmanagementprograminbreastcancer
AT hinshawdominiquec merlindeficiencyalterstheredoxmanagementprograminbreastcancer
AT alsheikhhebaa merlindeficiencyalterstheredoxmanagementprograminbreastcancer
AT chendongquan merlindeficiencyalterstheredoxmanagementprograminbreastcancer
AT samantrajeevs merlindeficiencyalterstheredoxmanagementprograminbreastcancer
AT shevdelalitaa merlindeficiencyalterstheredoxmanagementprograminbreastcancer